Atorvastatin Attenuates Aneurysmal Wall Inflammation in Vertebrobasilar Dissecting Aneurysms: Insights from a Randomized Controlled Trial
Posted inNeurology news Radiology

Atorvastatin Attenuates Aneurysmal Wall Inflammation in Vertebrobasilar Dissecting Aneurysms: Insights from a Randomized Controlled Trial

A randomized controlled trial demonstrates that 6-month atorvastatin treatment significantly reduces aneurysm wall enhancement and systemic inflammatory markers in patients with unruptured vertebrobasilar dissecting aneurysms, potentially offering a non-invasive stabilizing therapy for these high-risk lesions.
Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial
Posted innews Oncology Radiology

Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognitive function or quality of life, offering a promising new treatment paradigm.
Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage
Posted inNeurology news Radiology

Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage

While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectories, and specific subgroups with moderate hematoma volumes.
Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC
Posted innews Oncology Radiology

Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC

The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extensive brain metastases, providing a safe, effective alternative to whole-brain radiotherapy.
Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease
Posted inNeurology news Radiology

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

This study establishes patient-centered amyloid PET thresholds for tauopathy onset, revealing that age and sex significantly influence the transition from amyloidosis to tau accumulation. These personalized cut-offs better predict cognitive decline and offer a more precise framework for clinical intervention in Alzheimer's disease.
Emergent Carotid Stenting During Thrombectomy Superior for Tandem Lesion Stroke: Insights From the CERES-TANDEM Study
Posted inNeurology news Radiology

Emergent Carotid Stenting During Thrombectomy Superior for Tandem Lesion Stroke: Insights From the CERES-TANDEM Study

The CERES-TANDEM study provides Class II evidence that emergent carotid stenting (eCAS) during endovascular thrombectomy for tandem lesions significantly improves 90-day functional outcomes without increasing hemorrhagic risk, supporting its integration into clinical practice for acute anterior circulation ischemic stroke.
Refining Risk Stratification: The IsCHEMiA Score Outperforms Existing Models in Predicting Poststroke Epilepsy
Posted inNeurology news Radiology

Refining Risk Stratification: The IsCHEMiA Score Outperforms Existing Models in Predicting Poststroke Epilepsy

The IsCHEMiA score, an imaging-based risk model validated across international cohorts, offers superior prediction of poststroke epilepsy compared to previous tools. By integrating clinical and neuroimaging markers, it provides a precise framework for personalized management and the design of future antiepileptogenic clinical trials.